Pharma: Page 2
-
Sponsored by Avenga
Unlocking growth: How GenAI can help pharma companies convert new clients
GenAI is profoundly reshaping various facets of the pharmaceutical industry. Projections indicate that the global GenAI market in pharma will soar to $2258.1 million by 2032.
By Olena Domanska, Data Science Engineering Manager at Avenga • April 8, 2024 -
Viral return: 3 U.S. cases concerning experts
Infectious diseases that were “off the playing field” are now making a comeback.
By Meagan Parrish • April 5, 2024 -
Trendline
Emerging biotech
After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.
By PharmaVoice staff -
As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene
AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.
By Amy Baxter • April 3, 2024 -
A dementia-focused VC digs past anti-amyloid for neuroscience diamonds in the rough
Even as new drugs like Eisai and Biogen’s Leqembi make a splash in Alzheimer’s, VCs like the Dementia Discovery Fund have invested in the next wave of therapies.
By Michael Gibney • April 2, 2024 -
With a rise in animal-human organ transplants, a drugmaker aims for a new standard of care
Eledon Pharmaceuticals is developing a drug that could facilitate organ transplants from animals to humans as the procedure gains steam.
By Kelly Bilodeau • April 1, 2024 -
Q&A
To advance women’s leadership, an effort ‘has to be purposeful,’ says EMD Serono exec
Gender diversity in leadership “doesn’t just happen,” — it requires institutional change, from investing in women’s startups to providing more generous family leave.
By Alexandra Pecci • April 1, 2024 -
To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach
Rivus’ controlled metabolic accelerators are an emerging new potential competitor to popular weight loss and diabetes drugs from Novo Nordisk and Eli Lilly.
By Amy Baxter • March 29, 2024 -
Takeda plots ‘unprecedented patient diversity’ for psoriasis drug that could compete with BMS
Ahead of more guidance from the FDA on diversity in clinical trials, Takeda is aiming to beat industry standards.
By Amy Baxter • March 27, 2024 -
Alnylam turns to genealogy to find rare disease patients through family trees
A vastly underdiagnosed rare disease presents a challenge to Alnylam’s commercial team, but a family health road trip has patients talking about their hereditary risk.
By Michael Gibney • March 26, 2024 -
Q&A
Why a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim
Deborah Reardon is leading a new pillar that asks, “Are we looking at this from a patient lens and not from a Boehringer lens?”
By Alexandra Pecci • March 25, 2024 -
Who’s getting left behind in the weight loss bonanza?
As the new weight loss drugs take the world by storm, companies in other areas are battening the hatches for when slimmer patients need fewer medical interventions.
By Kelly Bilodeau • March 25, 2024 -
Profile
The pharma ‘fixer’ now helping Gates MRI’s tuberculosis battle
After getting her start as a nurse, Debra Weiss worked her way up the corporate ladder and is now COO of Gates MRI, which just launched its first phase 3 trial for tuberculosis.
By Alexandra Pecci • March 22, 2024 -
Q&A
An ocean of answers in a single cell — how proteomics can lead to better drugs
New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.
By Michael Gibney • March 21, 2024 -
With historic MASH approval, Madrigal preps for launch and a public offering
After snagging the first approval for MASH, Madrigal Pharmaceuticals’ drug is primed to become a blockbuster.
By Amy Baxter • March 20, 2024 -
Q&A // Biotech Spotlight
GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.
Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.
By Alexandra Pecci • March 19, 2024 -
As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help
A rebound in M&A seems to be on the docket, but analysts are warning companies to be intentional about where they go with it.
By Michael Gibney • March 19, 2024 -
Ex-Novartis exec sets out to create ‘Apple of AI’
Aily Labs’ tech makes predictive business decisions for life science companies and comes from a need its founder witnessed in Big Pharma.
By Kelly Bilodeau • March 18, 2024 -
5 Big Pharma CEOs who saw major pay bumps in 2023
Pharma’s recent wins have led to pay windfalls for several company leaders.
By Amy Baxter • March 18, 2024 -
After Amylyx drug failure, what’s next for ALS?
The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.
By Meagan Parrish • March 15, 2024 -
Q&A
Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake
A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.
By Michael Gibney • March 14, 2024 -
As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients
As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.
By Alexandra Pecci • March 12, 2024 -
The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs
Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.
By Michael Gibney • March 12, 2024 -
Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D
The Blackstone Life Sciences-backed company plans to focus on later-stage assets to help derisk development.
By Kelly Bilodeau • March 11, 2024 -
COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter
With COVID-19 vaccine sales dying down, Pfizer and Moderna turn to growth in different ways to cement their status as mRNA leaders.
By Amy Baxter • March 11, 2024 -
Sponsored by MMIT
Why pharma should prioritize the patient journey: A survivor’s story
One rare disease survivor’s diagnosis experience highlights the need for pharma companies to better understand the patient journey.
By Carolyn Zele, Solution Consulting Advisor, MMIT • March 11, 2024